Document Detail

Nanoparticulate Drug Delivery in Pregnancy: Placental Passage and Fetal Exposure.
MedLine Citation:
PMID:  21342124     Owner:  NLM     Status:  Publisher    
During the past decade there has been an explosion in the number of nanoparticulate drugs or drug delivery systems being explored, developed and marketed for the treatment and prevention of human diseases. While the potential dangers of drug administration in pregnancy are well known, there are circumstances where the benefits of maternal drug administration are perceived to outweigh the risks to the fetus. Hence, the administration of potentially harmful drugs in pregnancy is surprisingly common. Nanoparticulate delivery systems offer a potential avenue for delivering therapeutics to maternal tissues with minimal risk of incidental fetal exposure, depending on the ability of the nanoparticle in question to cross the placenta. As the conduit to the fetus, the placenta is both a drug target and a drug barrier, as well as a potential target of any toxicity. Limited studies on this topic show considerable uncertainty regarding the transplacental passage of nanoparticles, and our understanding of the criteria that determine transferability is poor. Despite the fact that the toxicity caused by environmental and man-made nanoparticulates has been widely studied in various organ systems, data on the effects of maternal nanoparticle exposure on human fetal tissues are lacking, although studies in rodents indicate that caution is justified. In this review, we examine the evidence relating to the potential toxicity of nanoparticles in pregnancy, the ability of the placenta to take up and transfer nanoparticles to the fetus, and the theoretical benefits and risks of administration of nanoparticle-based therapeutics in pregnancy.
Vinith Menezes; Antoine Malek; Jeffrey A Keelan
Related Documents :
21409544 - Fetal mri clues to diagnose cloacal malformations.
21334614 - The first successful paternity through in vitro fertilization-intracytoplasmic sperm in...
21413034 - Prenatal ultrasonographic measurement of the fetal iliac angle during the first and sec...
15695314 - What is the 'ideal' duration of progesterone supplementation before the transfer of cry...
9581094 - Practical approaches for estimating prepregnant body weight.
12589894 - Frequency of occurrence of the f wave in distal flexor muscles as a function of hypnoti...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-22
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  -     ISSN:  1873-4316     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-2-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Women's and Infant's Health Research Laboratories, School of Women's and Infant's Health, University of Western Australia, King Edward Memorial Hospital, 374 Bagot Rd, Subiaco, Perth, WA 6008, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nitric Oxide in Normal and Preeclamptic Pregnancy.
Next Document:  The Function of Cytochrome P450 1A1 Enzyme (CYP1A1) and Aryl Hydrocarbon Receptor (AhR) in the Place...